4.5 Article

Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study

Journal

ADVANCES IN THERAPY
Volume 39, Issue 6, Pages 2468-2486

Publisher

SPRINGER
DOI: 10.1007/s12325-021-01970-w

Keywords

Biologics; Tumor necrosis factor-alpha inhibitors; Treatment persistence; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Spondyloarthritis

Funding

  1. Merck Sharp Dohme Corp.

Ask authors/readers for more resources

This study investigated the direct and indirect costs associated with non-persistence with subcutaneous TNF-alpha inhibitors in inflammatory arthritis patients in Sweden. The results showed that patients who remained persistent with treatment incurred significantly lower healthcare costs compared to patients who discontinued treatment, highlighting the economic impact of treatment persistence.
Objective A few studies have suggested that patients with inflammatory arthritis (IA) who remain persistent with subcutaneous TNF-alpha inhibitors (SC-TNFi) incur lower health care costs than patients who discontinue treatment, whereas data on the impact of non-persistence on indirect costs are largely lacking. Furthermore, existing estimates are based on fixed follow-ups, in relation to treatment initiation, and therefore do not measure costs in direct relation to treatment discontinuation. Therefore, by capturing costs in direct relation to treatment discontinuation, this study aimed to estimate direct and indirect costs associated with non-persistence with SC-TNFis in IA. Methods Adult Swedish biologic-naive IA patients initiating biologic treatment with a SC-TNFi (adalimumab, etanercept, certolizumab or golimumab) between May 6, 2010, and December 31, 2017, were identified in population-based registers with almost complete coverage. IA was defined as a diagnosis of rheumatic arthritis, ankylosing spondylitis/unspecified spondyloarthritis or psoriatic arthritis. Non-persistent patients were matched on propensity score to patients persistent with treatment by at least an additional 12 months. This enabled comparisons of direct healthcare costs and indirect costs for sick leave and disability pension, respectively, 12 months before and 12 months after treatment discontinuation. Results A balanced cohort of 486 matched pairs was generated. The total direct and indirect costs were significantly higher among non-persistent patients already during the 12 months before index ($20,802 [18,335-23,429] vs. $16,600 [14,331-18,696]). However, while non-persistent patients increased their total direct and indirect costs, persistent patients significantly decreased the same, further widening the difference in costs during the 12-month period after index date ($22,161 [19,754-24,556] vs. $13,465 [11,415-15,729]). Conclusions Among biologic-naive Swedish IA patients treated with SC-TNFis, persistent patients incurred about 40% lower aggregated direct and indirect costs compared to non-persistent patients the year following SC-TNFi discontinuation. This highlights the impact of treatment persistence from an economic viewpoint, adding further aspects to the clinical perspective.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available